Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/31/2012 - 2:02pm.

  2. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    ... and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage ...

    Research Article last updated 04/08/2015 - 11:21am.

  4. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... has been combined with other novel agents such as lenalidomide , histone deacetylase inhibitors and growth factors in the hope ...

    Research Article last updated 05/14/2013 - 2:48pm.

  6. Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional

    ... value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an ...

    Research Article last updated 08/07/2013 - 9:18am.

  7. Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

    ... Azacitidine Lenalidomide Phase:  ... is a restricted distribution program for receiving lenalidomide ) Females of childbearing potential (FCBP)† must have a ...

    Clinical Trial last updated 06/06/2016 - 1:30pm.

  8. Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes

    ... of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their ...

    Research Article last updated 01/03/2013 - 9:57am.

  9. Myelodysplastic syndromes: an update on molecular pathology.

    ... hypomethylating drugs, immunomodulatory agents such as lenalidomide , and immunosuppressive drugs aimed at reversing the specific ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or ... that a majority of such patients who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, ...

    Research Review last updated 05/02/2016 - 9:32am.